Gossamer Bio Inc. (GOSS)
Gossamer Bio Statistics
Share Statistics
Gossamer Bio has 227.22M shares outstanding. The number of shares has increased by 0.44% in one year.
| Shares Outstanding | 227.22M |
| Shares Change (YoY) | 0.44% |
| Shares Change (QoQ) | 0.27% |
| Owned by Institutions (%) | 75.7% |
| Shares Floating | 182.6M |
| Failed to Deliver (FTD) Shares | 10 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 6.25M, so 2.76% of the outstanding shares have been sold short.
| Short Interest | 6.25M |
| Short % of Shares Out | 2.76% |
| Short % of Float | 3.59% |
| Short Ratio (days to cover) | 5.53 |
Valuation Ratios
The PE ratio is -3.62 and the forward PE ratio is -1.3. Gossamer Bio's PEG ratio is 0.05.
| PE Ratio | -3.62 |
| Forward PE | -1.3 |
| PS Ratio | 1.78 |
| Forward PS | 0.7 |
| PB Ratio | 6.94 |
| P/FCF Ratio | -59.01 |
| PEG Ratio | 0.05 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Gossamer Bio.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.88, with a Debt / Equity ratio of 6.88.
| Current Ratio | 6.88 |
| Quick Ratio | 6.88 |
| Debt / Equity | 6.88 |
| Debt / EBITDA | -5.08 |
| Debt / FCF | -58.5 |
| Interest Coverage | -5.2 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $796.53K |
| Profits Per Employee | $-392.56K |
| Employee Count | 144 |
| Asset Turnover | 0.36 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 893K |
| Effective Tax Rate | -1.61% |
Stock Price Statistics
The stock price has increased by -10.81% in the last 52 weeks. The beta is 1.86, so Gossamer Bio's price volatility has been higher than the market average.
| Beta | 1.86 |
| 52-Week Price Change | -10.81% |
| 50-Day Moving Average | 1.19 |
| 200-Day Moving Average | 0.98 |
| Relative Strength Index (RSI) | 34.01 |
| Average Volume (20 Days) | 1.48M |
Income Statement
In the last 12 months, Gossamer Bio had revenue of 114.7M and earned -56.53M in profits. Earnings per share was -0.25.
| Revenue | 114.7M |
| Gross Profit | 114.7M |
| Operating Income | -59.92M |
| Net Income | -56.53M |
| EBITDA | -39.97M |
| EBIT | -44.12M |
| Earnings Per Share (EPS) | -0.25 |
Balance Sheet
The company has 46.07M in cash and 202.88M in debt, giving a net cash position of -156.81M.
| Cash & Cash Equivalents | 46.07M |
| Total Debt | 202.88M |
| Net Cash | -156.81M |
| Retained Earnings | -1.27B |
| Total Assets | 315.29M |
| Working Capital | 264.88M |
Cash Flow
In the last 12 months, operating cash flow was -3.47M and capital expenditures 0, giving a free cash flow of -3.47M.
| Operating Cash Flow | -3.47M |
| Capital Expenditures | 0 |
| Free Cash Flow | -3.47M |
| FCF Per Share | -0.02 |
Margins
Gross margin is 100%, with operating and profit margins of -52.24% and -49.28%.
| Gross Margin | 100% |
| Operating Margin | -52.24% |
| Pretax Margin | -48.5% |
| Profit Margin | -49.28% |
| EBITDA Margin | -34.84% |
| EBIT Margin | -52.24% |
| FCF Margin | -3.02% |
Dividends & Yields
GOSS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for GOSS is $8.5, which is 758.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $8.5 |
| Price Target Difference | 758.6% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | -4.3 |
| Piotroski F-Score | 4 |